Tocilizumab in Systemic Juvenile Idiopathic Arthritis: Response Differs by Disease Duration at Medication Initiation and by Phenotype of Disease

Objective: We performed a single-center retrospective study to determine the different efficacy of tocilizumab (TCZ) in the early and late stages and in three phenotypic subgroups (monocyclic, polycyclic, and persistent) of systemic juvenile idiopathic arthritis (sJIA). Methods: Clinical and serolog...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Xin, Tang, Wenjing, Zhang, Zhiyong, Zhang, Yu, Luo, Chong, Tang, Xuemei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pediatrics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8606744/
https://www.ncbi.nlm.nih.gov/pubmed/34820342
http://dx.doi.org/10.3389/fped.2021.735846

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8606744/
https://www.ncbi.nlm.nih.gov/pubmed/34820342
http://dx.doi.org/10.3389/fped.2021.735846

Ejemplares similares